Liquid diabetes drug could be Game-Changer for kids
NCT ID NCT02375828
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 22 times
Summary
This study tested a new liquid version of the diabetes drug glibenclamide in 10 children with neonatal diabetes caused by a genetic mutation. The goal was to see if the liquid form is easier for children to take and works as well as the standard pill. The study measured how acceptable and tolerable the liquid medicine was for the children.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEONATAL DIABETES SECONDARY TO MUTATION IN THE POTASSIUM CHANNEL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hôpital Universitaire Necker Enfants Malades
Paris, 7501, France
Conditions
Explore the condition pages connected to this study.